Epitor Therapeutics

Company Type: Therapeutic development

Main focus: Developing CRISPR-based epigenetic editors to treat various diseases

Company stage: Pre-clinical

Diseases: Rett Syndrome and other neurodevelopmental diseases

Genome-editing tool: CRISPR-CasNano

Funding stage: Early Stage VC

Location: New York, New York, USA

Website: epitortx.com

Pipeline:

Partners:

Epitor Therapeutics, a biotechnology company specialising in epigenetic editing, is developing new treatments for various diseases by targeting gene regulation via the epigenome. The company's proprietary Cas enzyme, CasNano, is an ultracompact Cas protein with less than 400 amino acids. CasNano is compatible with a range of effectors and aims to control gene transcription via epigenetic modifications. Its compact size aims to overcome the delivery challenges associated with current gene-editing tools. Epitor's primary epigenetic-editing programme focuses on investigating epigenetic editing as a treatment for Rett Syndrome.